CCIA
BCRX icon

Campbell & Co Investment Adviser’s BioCryst Pharmaceuticals BCRX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-68,559
Closed -$535K – 1076
2025
Q4 		$535K Sell
68,559
-40,995
-37% -$296K 0.03% 801
2025
Q3 		$832K Sell
109,554
-302,964
-73% -$2.52M 0.06% 493
2025
Q2 		$3.7M Buy
412,518
+390,834
+1,802% +$3.64M 0.23% 85
2025
Q1 		$163K Buy
+21,684
New +$175K 0.01% 963
2024
Q1 		– Sell
-20,702
Closed -$124K – 1107
2023
Q4 		$124K Buy
+20,702
New +$120K 0.01% 1056

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Campbell & Co Investment Adviser's BCRX Position: Q1 2026 in Review

Campbell & Co Investment Adviser sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2026, closing a stake of 68,559 shares — an estimated $535K sold.

Campbell & Co Investment Adviser first reported a position in BCRX in Q4 2023 and held it in 5 quarters. The position peaked at $3.7M in Q2 2025. 302 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Campbell & Co Investment Adviser reported no remaining BioCryst Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 68,559 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $535K.
  • Campbell & Co Investment Adviser first reported a position in BioCryst Pharmaceuticals in Q4 2023 and held it in 5 quarters.
  • Campbell & Co Investment Adviser's BioCryst Pharmaceuticals position peaked at $3.7M in Q2 2025.
  • 302 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.